ଆକ୍ଲିଡିନିଅମ ବ୍ରୋମାଇଡ

<span title="International nonproprietary name (INN): <nowiki>Mr. Ibrahem/Aclidinium</nowiki>">Mr. Ibrahem/Aclidinium
Clinical data
Trade names	Bretaris Genuair, Eklira Genuair, Tudorza Pressair
Other names	Aclidinium bromide
AHFS/Drugs.com	Monograph
License data	<abbr class="country-name" title="<nowiki>United States</nowiki>">US DailyMed: Aclidinium; <abbr class="country-name" title="<nowiki>United States</nowiki>">US FDA: Aclidinium;
Routes of; ; administration	Inhalation
Drug class	Long-acting muscarinic antagonist (LAMA)
Legal status
Legal status	<abbr class="country-name" title="<nowiki>United States</nowiki>">US: ℞-only ; <abbr class="country-name" title="<nowiki>European Union</nowiki>">EU: Rx-only ;
Pharmacokinetic data
Bioavailability	<5% (in system); ; 30% (in lung)
Metabolism	Ester hydrolysis
Elimination half-life	2–3 hrs
Duration of action	>24 hrs
Excretion	65% urine, 33% faeces
Identifiers
	IUPAC name [(8R)-1-(3-Phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-8-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate bromide;
Chemical and physical data
Formula	C26H30BrNO4S2
Molar mass	564.55 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [Br-].O=C(O[C@@H]3C2CC[N+](CCCOc1ccccc1)(CC2)C3)C(O)(c4sccc4)c5sccc5;
	InChI InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1 ; Key:XLAKJQPTOJHYDR-QTQXQZBYSA-M ;
	(what is this?) (verify)

ଆକ୍ଲିଡିନିଅମ ବ୍ରୋମାଇଡ
Clinical data
Trade names	Bretaris Genuair, Eklira Genuair, Tudorza Pressair
Synonyms	Aclidinium bromide
AHFS/Drugs.com	monograph
data	US DailyMed: Aclidinium;
Routes of; administration	Inhalation
Legal status
Legal status	US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	<5% (in system); 30% (in lung)
Metabolism	Ester hydrolysis
Elimination half-life	2–3 hrs
Duration of action	>24 hrs
Excretion	65% urine, 33% faeces
Identifiers
	IUPAC name [(8R)-1-(3-Phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-8-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate bromide;
ECHA InfoCard	100.260.213
Chemical and physical data
Formula	C26H30BrNO4S2
Molar mass	୫୬୪.୫୫ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [Br-].O=C(O[C@@H]3C2CC[N+](CCCOc1ccccc1)(CC2)C3)C(O)(c4sccc4)c5sccc5;
	InChI InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1 ; Key:XLAKJQPTOJHYDR-QTQXQZBYSA-M ;
(verify)

ଆକ୍ଲିଡିନିଅମ ବ୍ରୋମାଇଡ ଏକ ଔଷଧ ଯାହା କ୍ରନିକ୍ ଅବଷ୍ଟ୍ରକ୍ଟିଭ୍ ଫୁସଫୁସ ରୋଗ (COPD)ର ରକ୍ଷଣାବେକ୍ଷଣ ଚିକିତ୍ସା ପାଇଁ ଦିଆଯାଏ । ^[୧] ଏହା ଜୀବନ ଯାପନ ପ୍ରଳୀରେ ଉନ୍ନତି ଆଣିବା ଯୋଗୁ ଡାକ୍ତରଖାନାରେ ଭର୍ତ୍ତି ହେବ ଆବଶ୍ୟକ ହୁଏ; କିନ୍ତୁ ମୃତ୍ୟୁ ବିପଦ କିମ୍ବା ଷ୍ଟେରଏଡ୍ର ଆବଶ୍ୟକତା ଉପରେ ପ୍ରଭାବ ପକାଇବ ନାହିଁ । ^[୨] ଏହା ଟାୟୋଟ୍ରୋପିୟମ୍ କିମ୍ବା ଏଲଏଏମଏ (LAMA) ଶ୍ରେଣୀର ଅନ୍ୟ ଔଷଧଠାରୁ ଭିନ୍ନ କି ନୁହେଁ ତାହା ଅସ୍ପଷ୍ଟ । ^[୩] ଏହା ଏକ ଶୁଖିଲା ପାଉଡର ଆକାରରେ ମିଳେ ଓ ଆଘ୍ରାଣଦ୍ୱାରା ବ୍ୟବହୃତ ହୁଏ । ^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବିନ୍ଧା, କାଶ, ନାକ ଏବଂ ଗଳାର ପ୍ରଦାହ ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ । ^[୧] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ତରଳ ଝାଡ଼ା, ବ୍ରୋଙ୍କୋସ୍ପାଜ୍ମ ଏବଂ ୟୁରିନାରି ରିଟେନସନ ହୋଇପାରେ । ^[୫] ^[୪] ଏହା ଏକ ଦୀର୍ଘକାଳୀନ କାର୍ଯ୍ୟ କରୁଥିବା ମସ୍କାରିନିକ୍ ଆଣ୍ଟାଗୋନିଷ୍ଟ୍ (LAMA) | ^[୪]

ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଆକ୍ଲିଡିନିଅମ ବ୍ରୋମାଇଡ ଅନୁମୋଦିତ ୨୦୧୨ ମସିହାରେ ହୋଇଥିଲା। ^[୧] ଯୁକ୍ତରାଜ୍ୟରେ ଏହାର ଏକ ମାସର ମୂଲ୍ୟ ୩୩ ପଉଣ୍ଡ । ^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶି ୨୦୨୧ ସୁଦ୍ଧା ପ୍ରାୟ ୫୬୦ ଡଲାର ଅଟେ। ^[୬] ଏହା ଫର୍ମୋଟେରୋଲ ସହିତ ମଧ୍ୟ ଏକତ୍ର ଉପଲବ୍ଧ । ^[୭]

ଆଧାର

1 2 3 4 "Aclidinium Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 15 July 2021.
↑ Ni, H; Soe, Z; Moe, S (2014). "Aclidinium bromide for stable chronic obstructive pulmonary disease". The Cochrane Database of Systematic Reviews (9): CD010509. doi:10.1002/14651858.CD010509.pub2. PMID 25234126.
↑ Ni, H; Soe, Z; Moe, S (2014). "Aclidinium bromide for stable chronic obstructive pulmonary disease". The Cochrane Database of Systematic Reviews (9): CD010509. doi:10.1002/14651858.CD010509.pub2. PMID 25234126.
1 2 3 "Aclidinium Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 January 2021. Retrieved 15 July 2021.
1 2 BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 260. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
↑ "Aclidinium Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 15 July 2021.
↑ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 260. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[autogen1-1] 1 2 3 4 "Aclidinium Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 15 July 2021.

[Cochrane2014-2] Ni, H; Soe, Z; Moe, S (2014). "Aclidinium bromide for stable chronic obstructive pulmonary disease". The Cochrane Database of Systematic Reviews (9): CD010509. doi:10.1002/14651858.CD010509.pub2. PMID 25234126.

[autogen3-3] Ni, H; Soe, Z; Moe, S (2014). "Aclidinium bromide for stable chronic obstructive pulmonary disease". The Cochrane Database of Systematic Reviews (9): CD010509. doi:10.1002/14651858.CD010509.pub2. PMID 25234126.

[autogen2-4] 1 2 3 "Aclidinium Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 January 2021. Retrieved 15 July 2021.

[BNF80-5] 1 2 BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 260. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[Gx2021-6] "Aclidinium Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 15 July 2021.

[autogen5-7] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 260. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]